EMA Validated Gene Therapy Application for MPS IIIA
European regulators have begun the formal review process for the AAV9 gene therapy rebisufligene etisparvovec.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize patient access when launching expensive new gene therapies?
The European Medicines Agency has validated the Marketing Authorisation Application for rebisufligene etisparvovec, a single-dose intravenous gene therapy designed to treat MPS IIIA. This validation marks the official start of the scientific review process for the treatment.
Why it matters
The therapy aims to address the significant unmet medical need for patients with MPS IIIA, a rare and progressive lysosomal storage disease caused by a deficiency in the sulfamidase enzyme.
Rebisufligene etisparvovec functions as a single-dose intravenous AAV9 gene therapy. The treatment is designed to address enzyme deficiency in patients with Sanfilippo syndrome Type A.
The players
European Medicines Agency
This is the primary EU regulatory body responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
Ultragenyx
This is the biopharmaceutical company developing and commercializing therapies for rare genetic diseases, including MPS IIIA.
The details
The EMA application for the gene therapy falls under the European Union's Joint Clinical Assessment framework, which streamlines the assessment process across member states. Additionally, the company behind the therapy has started regulatory engagement with health authorities in the United Kingdom and Saudi Arabia.
Timeline
September 17, 2026: The FDA approved rebisufligene etisparvovec.
October 2, 2026: The European Medicines Agency validated the Marketing Authorisation Application.
The Tech Race
The application process highlights the shift toward standardized cross-border regulatory frameworks in the European biotech sector. This framework aims to harmonize clinical assessment standards for advanced therapies across multiple nations.
The validation signifies progress toward wider therapeutic access for patients suffering from this rare genetic condition. Once approved, the therapy could offer a life-altering treatment option for those currently limited by the 15-year median life expectancy of the disease.
The takeaway
The EMA's validation is a critical step in bringing advanced gene therapies to international markets for rare, fatal pediatric diseases. Patients and caregivers should continue to monitor regulatory milestones in the EU, UK, and Saudi Arabia as the drug moves through the review process.
Further reading
For more information on the latest advancements in gene therapy, visit Biotech.
Live Poll
Do you trust pharmaceutical companies to prioritize patient access when launching expensive new gene therapies?
